Skip to main content

Table 5 Statistical analysis for all and distant recurrences in the TransATAC validation cohort

From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

Score Univariate Multivariable comparisons
CTS + signature vs CTS CTS + signature
LRχ2 p Value HR (95% CI) C-index (SE) ∆LRχ2 p Value HR (95% CI) C-index (SE)
All recurrences (n = 271, AR = 55)
 CTS 37.4 < 0.001 1.94 (1.57–2.40) 0.664 (0.020)
 10-Year signature 20.7 < 0.001 1.85 (1.42–2.41) 0.657 (0.029) 5.7 0.017 1.42 (1.07–1.89) 0.695 (0.023)
 BCI 25.0 < 0.001 2.07 (1.54–2.77) 0.679 (0.029) 9.5 0.002 1.62 (1.19–2.21) 0.711 (0.024)
 RS 11.1 < 0.001 1.52 (1.21–1.91) 0.607 (0.027) 5.8 0.016 1.35 (1.07–1.71) 0.683 (0.021)
 ROR 18.3 < 0.001 1.77 (1.36–2.31) 0.650 (0.030) 6.0 0.014 1.42 (1.07–1.87) 0.700 (0.024)
 IHC4 14.4 < 0.001 1.63 (1.28–2.10) 0.629 (0.029) 7.5 0.006 1.46 (1.12–1.91) 0.696 (0.023)
Distant recurrences (n = 271, DR = 41)
 CTS 46.7 < 0.001 2.25 (1.79–2.82) 0.689 (0.019)
 10-Year signature 26.4 < 0.001 2.24 (1.64–3.06) 0.694 (0.029) 8.5 0.004 1.65 (1.18–2.30) 0.733 (0.023)
 BCI 34.0 < 0.001 2.71 (1.91–3.84) 0.726 (0.028) 14.5 < 0.001 2.03 (1.40–2.95) 0.754 (0.023)
 RS 10.7 < 0.001 1.58 (1.23–2.03) 0.616 (0.029) 5.1 0.024 1.38 (1.06–1.79) 0.707 (0.020)
 ROR 21.3 < 0.001 2.05 (1.50–2.79) 0.680 (0.031) 7.5 0.006 1.58 (1.14–2.21) 0.736 (0.024)
 IHC4 17.9 < 0.001 1.87 (1.41–2.49) 0.658 (0.031) 9.8 0.002 1.68 (1.22–2.31) 0.731 (0.023)
  1. Abbreviations: AR All recurrences, DR Distant recurrences, CTS Clinical Treatment Score, BCI Breast Cancer Index, RS Recurrence score, ROR Risk of recurrence, LR Likelihood ratio
  2. Both univariate and multivariable analyses are presented. For each score, HRs per SD change are presented. Likelihood ratio test based on Cox proportional hazards models for univariate and multivariable analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS was used as a covariate in the multivariable regressions